# MHPAEA Causal Inference Study ğŸ§ ğŸ“Š

## Overview ğŸŒŸ
This project examines the causal effects of the **Mental Health Parity and Addiction Equity Act (MHPAEA)** on the utilization of mental health services and overall mental well-being. Enacted in 2008, the MHPAEA requires parity in treatment between mental health/substance use disorder (MH/SUD) benefits and medical/surgical benefits under group health plans and insurance coverage. The primary aim is to measure the **average treatment effect (ATE)** for individuals with private insurance (treatment group) compared to those without private insurance (control group).

Additionally, the project evaluates **heterogeneous treatment effects (HTE)** by income level to explore policy impacts across socioeconomic groups.

## Objective ğŸ¯
- **Primary Goals**:
  - Estimate the **causal effects** of MHPAEA on mental health service utilization and outcomes.
  - Assess the **heterogeneous treatment effects (HTE)** to determine whether the policy benefits vary across income groups.
- **Methodology**:
  - **Difference-in-Differences (DiD)**: To analyze pre- and post-policy effects.
  - **Doubly Robust Estimator**: To ensure robust ATE estimates by combining propensity score weighting with outcome regression.
  - **Subgroup Analysis**: Evaluate HTE by stratifying income groups.

## Data ğŸ“‘
- **Source**: National Survey on Drug Use and Health (NSDUH), collected by SAMHSA (2005â€“2020).
- **Treatment Group**: Individuals with private health insurance eligible for MHPAEA.
- **Control Group**: Individuals without private health insurance.
- **Key Variables**:
  - **Treatment**: Binary indicator for MHPAEA applicability (private insurance status).
  - **Outcomes**:
    - Annual healthcare facility visits.
    - Self-reported health status (1-5, higher is better).
    - Mental health index (0-24, lower is better).
  - **Covariates**: Age, gender, education level, marital status, household size, income group, etc.

## Approach ğŸ”
### 1. **Data Preprocessing** ğŸ§¹:
- Cleaned and merged datasets to include treatment, outcomes, and covariates.
- Standardized continuous variables and encoded categorical variables as needed.

### 2. **Propensity Score Matching (PSM)** ğŸ”„:
- Estimated propensity scores using logistic regression.
- Matched individuals from treatment and control groups to balance covariates.

### 3. **Difference-in-Differences (DiD)** ğŸ“‰:
- Applied DiD to estimate the ATE by comparing pre- and post-policy differences between groups.

### 4. **Doubly Robust Estimator** ğŸ‹ï¸â€â™‚ï¸:
- Combined propensity score weighting with outcome regression to estimate ATE.
- Used this method to improve robustness against model misspecification.

### 5. **Heterogeneous Treatment Effects (HTE)** ğŸ“Š:
- Stratified the sample by income levels to compare treatment effects across socioeconomic groups.

## Results ğŸ“Š
- **Overall Effects** (ATE):
  - **Annual healthcare visits**: Increased by 0.086.
  - **Self-reported health status**: Improved by 0.107.
  - **Mental health index**: Improved by 0.182.
- **HTE by Income Level**:
  - The most significant improvements were observed in lower-income groups, suggesting the policy had the greatest impact on underserved populations.
  - Middle-income groups experienced relatively weaker effects, highlighting potential areas for policy refinement.

## Policy Implications ğŸ’¡
- MHPAEA effectively improved mental health service utilization and outcomes, particularly for lower-income groups.
- Future policies should address gaps in effectiveness among middle-income groups to maximize overall societal benefit.

## Limitations âš™ï¸
- Potential unobserved confounders may still bias results.
- Long-term effects require further investigation.

## Future Work ğŸš€
- Enhance robustness of subgroup analyses using advanced matching methods.
- Explore the policyâ€™s impact on broader mental health outcomes, such as long-term economic productivity and quality of life.

---

# MHPAEA ì¸ê³¼ì¶”ë¡  ì—°êµ¬ ğŸ§ ğŸ“Š

## ê°œìš” ğŸŒŸ
ì´ í”„ë¡œì íŠ¸ëŠ” **Mental Health Parity and Addiction Equity Act (MHPAEA)** ê°€ ì •ì‹ ê±´ê°• ì„œë¹„ìŠ¤ ì´ìš©ê³¼ ì „ë°˜ì ì¸ ì •ì‹ ê±´ê°• ìƒíƒœì— ë¯¸ì¹œ ì¸ê³¼ì  ì˜í–¥ì„ ë¶„ì„í•©ë‹ˆë‹¤. 2008ë…„ì— ì œì •ëœ MHPAEAëŠ” ë‹¨ì²´ ê±´ê°•ë³´í—˜ê³¼ ì˜ë£Œ/ì™¸ê³¼ í˜œíƒì„ ì œê³µí•˜ëŠ” ë³´í—˜ì—ì„œ ì •ì‹ ê±´ê°•/ì•½ë¬¼ ì‚¬ìš© ì¥ì• (MH/SUD) í˜œíƒ ê°„ì˜ í‰ë“±ì„ ë³´ì¥í•˜ë„ë¡ ìš”êµ¬í•©ë‹ˆë‹¤. ì´ ì—°êµ¬ì˜ ì£¼ìš” ëª©í‘œëŠ” ë¯¼ê°„ ë³´í—˜ ê°€ì…ì(ì¹˜ë£Œ ì§‘ë‹¨)ì™€ ë¹„ê°€ì…ì(ëŒ€ì¡° ì§‘ë‹¨) ê°„ì˜ **í‰ê·  ì²˜ë¦¬ íš¨ê³¼(ATE)** ë¥¼ ì¸¡ì •í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.

ë˜í•œ, ì†Œë“ ìˆ˜ì¤€ì— ë”°ë¥¸ **ì´ì§ˆì  ì²˜ë¦¬ íš¨ê³¼(HTE)** ë¥¼ í‰ê°€í•˜ì—¬ ì •ì±…ì˜ ì‚¬íšŒê²½ì œì  ì˜í–¥ì„ íƒêµ¬í•©ë‹ˆë‹¤.

## ëª©í‘œ ğŸ¯
- **ì£¼ìš” ëª©í‘œ**:
  - MHPAEAê°€ ì •ì‹ ê±´ê°• ì„œë¹„ìŠ¤ ì´ìš© ë° ê²°ê³¼ì— ë¯¸ì¹œ **ì¸ê³¼ì  íš¨ê³¼** ë¥¼ ì¶”ì •í•©ë‹ˆë‹¤.
  - ì†Œë“ ê³„ì¸µì— ë”°ë¥¸ **ì´ì§ˆì  ì²˜ë¦¬ íš¨ê³¼(HTE)** ë¥¼ í‰ê°€í•˜ì—¬ ì •ì±… í˜œíƒì˜ ì°¨ì´ë¥¼ ë¶„ì„í•©ë‹ˆë‹¤.
- **ë°©ë²•ë¡ **:
  - **ì´ì¤‘ì°¨ë¶„ë²•(DiD)**: ì •ì±… ì‹œí–‰ ì „í›„ì˜ íš¨ê³¼ë¥¼ ë¶„ì„í•©ë‹ˆë‹¤.
  - **Doubly Robust Estimator**: Propensity Scoreì™€ ê²°ê³¼ íšŒê·€ ëª¨ë¸ì„ ê²°í•©í•´ ë” ê°•ê±´í•œ ATEë¥¼ ì¶”ì •í•©ë‹ˆë‹¤.
  - **ì†Œê·¸ë£¹ ë¶„ì„**: ì†Œë“ ê³„ì¸µë³„ HTEë¥¼ í‰ê°€í•©ë‹ˆë‹¤.

## ë°ì´í„° ğŸ“‘
- **ì¶œì²˜**: SAMHSAì—ì„œ ìˆ˜ì§‘í•œ ì•½ë¬¼ ì‚¬ìš© ë° ê±´ê°•ì— ê´€í•œ êµ­ê°€ ì¡°ì‚¬(NSDUH) ë°ì´í„°(2005â€“2020).
- **ì¹˜ë£Œ ì§‘ë‹¨**: MHPAEAê°€ ì ìš©ë˜ëŠ” ë¯¼ê°„ ê±´ê°•ë³´í—˜ ê°€ì…ì.
- **ëŒ€ì¡° ì§‘ë‹¨**: ë¯¼ê°„ ê±´ê°•ë³´í—˜ì— ê°€ì…ë˜ì§€ ì•Šì€ ëŒ€ìƒì.
- **ì£¼ìš” ë³€ìˆ˜**:
  - **ì²˜ì¹˜**: MHPAEA ì ìš© ì—¬ë¶€(ë¯¼ê°„ ë³´í—˜ ê°€ì… ì—¬ë¶€ë¡œ êµ¬ë¶„ëœ ì´ì§„ ë³€ìˆ˜).
  - **ê²°ê³¼ ë³€ìˆ˜**:
    - ì—°ê°„ ì˜ë£Œì‹œì„¤ ë°©ë¬¸ íšŸìˆ˜.
    - ìê¸° ë³´ê³  ê±´ê°• ìƒíƒœ(1-5, ë†’ì„ìˆ˜ë¡ ê±´ê°•).
    - ì •ì‹ ê±´ê°• ì§€ìˆ˜(0-24, ë‚®ì„ìˆ˜ë¡ ê±´ê°•).
  - **ê³µë³€ëŸ‰**: ì—°ë ¹, ì„±ë³„, êµìœ¡ ìˆ˜ì¤€, í˜¼ì¸ ìƒíƒœ, ê°€êµ¬ì› ìˆ˜, ì†Œë“ ìˆ˜ì¤€ ë“±.

## ì ‘ê·¼ë²• ğŸ”
### 1. **ë°ì´í„° ì „ì²˜ë¦¬** ğŸ§¹:
- ì²˜ì¹˜, ê²°ê³¼ ë³€ìˆ˜, ê³µë³€ëŸ‰ì„ í¬í•¨í•˜ë„ë¡ ë°ì´í„° ì •ë¦¬ ë° ë³‘í•©.
- ì—°ì†í˜• ë³€ìˆ˜ëŠ” í‘œì¤€í™”í•˜ê³  ë²”ì£¼í˜• ë³€ìˆ˜ëŠ” ì¸ì½”ë”©.

### 2. **Propensity Score Matching (PSM)** ğŸ”„:
- ë¡œì§€ìŠ¤í‹± íšŒê·€ë¥¼ ì‚¬ìš©í•´ Propensity Scoreë¥¼ ì¶”ì •.
- Propensity Scoreë¥¼ ê¸°ë°˜ìœ¼ë¡œ ì¹˜ë£Œ ì§‘ë‹¨ê³¼ ëŒ€ì¡° ì§‘ë‹¨ì„ ë§¤ì¹­í•˜ì—¬ ê³µë³€ëŸ‰ ê· í˜•ì„ ë§ì¶¤.

### 3. **ì´ì¤‘ì°¨ë¶„ë²•(DiD)** ğŸ“‰:
- ì •ì±… ì‹œí–‰ ì „í›„ ë‘ ì§‘ë‹¨ ê°„ ì°¨ì´ë¥¼ ë¹„êµí•˜ì—¬ ATEë¥¼ ì¶”ì •.

### 4. **Doubly Robust Estimator** ğŸ‹ï¸â€â™‚ï¸:
- Propensity Scoreì™€ ê²°ê³¼ íšŒê·€ ëª¨ë¸ì„ ê²°í•©í•˜ì—¬ ATEë¥¼ ì¶”ì •.
- ëª¨ë¸ ëª…ì„¸ ì˜¤ë¥˜ì— ê°•ê±´í•œ ì¶”ì •ì„ ìœ„í•´ í™œìš©.

### 5. **ì´ì§ˆì  ì²˜ë¦¬ íš¨ê³¼(HTE)** ğŸ“Š:
- ì†Œë“ ìˆ˜ì¤€ë³„ë¡œ ë°ì´í„°ë¥¼ ë‚˜ëˆ„ì–´ ì •ì±… íš¨ê³¼ë¥¼ ë¹„êµ.

## ê²°ê³¼ ğŸ“Š
- **ì „ì²´ íš¨ê³¼(ATE)**:
  - **ì—°ê°„ ì˜ë£Œì‹œì„¤ ë°©ë¬¸ íšŸìˆ˜**: 0.086 ì¦ê°€.
  - **ìê¸° ë³´ê³  ê±´ê°• ìƒíƒœ**: 0.107 ê°œì„ .
  - **ì •ì‹ ê±´ê°• ì§€ìˆ˜**: 0.182 ê°œì„ .
- **ì†Œë“ ê³„ì¸µë³„ HTE**:
  - ì €ì†Œë“ì¸µ ê·¸ë£¹ì—ì„œ ê°€ì¥ í° ê°œì„  íš¨ê³¼ê°€ ë‚˜íƒ€ë‚¬ìœ¼ë©°, ì •ì±…ì´ ì†Œì™¸ ê³„ì¸µì— í° ì˜í–¥ì„ ë¯¸ì¹œ ê²ƒìœ¼ë¡œ ë³´ì„.
  - ì¤‘ê°„ ì†Œë“ ê·¸ë£¹ì—ì„œëŠ” ìƒëŒ€ì ìœ¼ë¡œ ì•½í•œ íš¨ê³¼ê°€ ê´€ì°°ë˜ì–´ ì •ì±… ê°œì„ ì˜ ì—¬ì§€ê°€ ìˆìŒ.

## ì •ì±…ì  ì‹œì‚¬ì  ğŸ’¡
- MHPAEAëŠ” ì •ì‹ ê±´ê°• ì„œë¹„ìŠ¤ ì´ìš©ê³¼ ê²°ê³¼ë¥¼ ê°œì„ í•˜ëŠ” ë° íš¨ê³¼ì ì´ì—ˆìœ¼ë©°, íŠ¹íˆ ì €ì†Œë“ì¸µì—ì„œ ë‘ë“œëŸ¬ì§„ íš¨ê³¼ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤.
- í–¥í›„ ì •ì±…ì€ ì¤‘ê°„ ì†Œë“ ê·¸ë£¹ì—ì„œì˜ íš¨ê³¼ë¥¼ ê°•í™”í•˜ì—¬ ì‚¬íšŒì  í˜œíƒì„ ê·¹ëŒ€í™”í•´ì•¼ í•©ë‹ˆë‹¤.

## í•œê³„ âš™ï¸
- ì ì¬ì  í˜¼ë€ ë³€ìˆ˜(Confounder)ì˜ ëˆ„ë½ ê°€ëŠ¥ì„±ì´ ì—¬ì „íˆ ì¡´ì¬í•©ë‹ˆë‹¤.
- ì¥ê¸°ì ì¸ íš¨ê³¼ë¥¼ í‰ê°€í•˜ê¸° ìœ„í•´ ì¶”ê°€ ì—°êµ¬ê°€ í•„ìš”í•©ë‹ˆë‹¤.

## í–¥í›„ ê³¼ì œ ğŸš€
- ì†Œê·¸ë£¹ ë¶„ì„ì˜ ê°•ê±´ì„±ì„ ë†’ì´ê¸° ìœ„í•´ ê³ ê¸‰ ë§¤ì¹­ ê¸°ë²•ì„ í™œìš©í•©ë‹ˆë‹¤.
- ì •ì±…ì´ ê²½ì œì  ìƒì‚°ì„±ê³¼ ì‚¶ì˜ ì§ˆê³¼ ê°™ì€ ì¥ê¸°ì ì¸ ì •ì‹ ê±´ê°• ê²°ê³¼ì— ë¯¸ì¹œ ì˜í–¥ì„ íƒêµ¬í•©ë‹ˆë‹¤.
